JPMorgan raised the firm’s price target on BeOne Medicines (ONC) to $345 from $321 and keeps an Overweight rating on the shares. The firm removed previously assumed Inflation Reduction Act price negotiation for Brukinsa following the One Big Beautiful Bill passage. The analyst believes Brukinsa is now exempt from IRA price negotiations as the bill exempts drugs from negotiation that have more than one orphan indication.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines price target raised to $349 from $311 at RBC Capital
- BeOne announces EC approval of Tevimbra in combination with chemotherapy
- Buy Rating for BeOne Medicines: Promising Developments and Strategic Positioning
- Beigene’s BG-68501 Study: A Potential Game-Changer in Oncology
- Jazz Pharmaceuticals and BeiGene’s Promising Phase 3 Study for Advanced Gastric and Esophageal Cancers